Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Zacks Investment Research on MSN13h
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS StudySwiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...
Clinical Trials Arena on MSN16h
Roche’s high-dose Ocrevus fails primary endpoint in MS trialHigher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...
A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...
Columnist Ahna Crum spent years trying to go it alone. Now she knows that freedom comes when she's flocking together with ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback